Impulse Control Disorder, Parkinson Disease
Conditions
Keywords
Speech
Brief summary
Speech assessment is a substudy to the STIMPulseControl study (hereinafter referred to as the main study), where audio recordings of patients voices will be recorded as part of a speech analysis in the main study, for this optional ancillary study.
Detailed description
Speech of all study patients enrolled in the STIMPulseControl main study will be recorded at three points of time in a standardized way. Following this ancillary protocol, patients speech will be recorded at the baseline visit (preoperatively), at the 6-months visit and at the 12-months visit postoperatively. For the baseline speech assessment the same protocol will be performed in chronic medication conditions. At 12-month follow up, we will repeat the speech protocol in chronic medication and stimulation condition. The recordings will be done in each centre in a decentralized way and the audio files will be produced according to a standardized protocol, and assisted by a step-by-step guided speech recording software. Main aims and hypothesis for automated speech analysis study are safety measures for surgical interventions in PD assessment of parkinsonian (hypokinetic) motor speech features outcome after STN-DBS, assessment of dyskinetic (hyperkinetic) motor speech features outcome after STN-DBS, assessment of capsular speech features outcome after STN-DBS in PD emotional and cognitive speech outcomes to be used in surgical and pharmacological interventions in PD assessment of acoustic and linguistic speech features as proxy for behaviour and cognitive changes in PD, comparison of emotional and cognitive speech outcomes before and 1-year after STN-DBS + BMT vs BMT alone.
Interventions
PROCEDUREbilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper
Best medical treatment according to widely accepted expert consensus Paper
DRUGbest medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper
Best medical treatment according to widely accepted consensus Paper
Sponsors
Czech Technical University in Prague
Insel Gruppe AG, University Hospital Bern
Philipps University Marburg
University Hospital Schleswig-Holstein
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Steffen Paschen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Please refer to main study (STIMPulseControl KKS-313)
Exclusion criteria
Please refer to main study (STIMPulseControl KKS-313)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Titel: PART 1: Assessment of parkinsonian motor speech features (hypokinetic dysarthria) outcome after STN-DBS | 12 months | primary aim: To globally assess motor speech features of PD change after STN-DBS intervention. Outcome: A compound score resulting from the normalized average of the main speech domains of hypokinetic dysarthria (i.e.phonation, articulation, prosody and timing) will be analyzed. For example, as proxy of phonation/voice quality, harmonics-to-noise ratio will be used. For the assessment of articulation changes, voice to onset (VOT) and Resonant frequency attenuation (RFA) will be assessed. Monopitch, will be assessed using the standard deviation of fundamental frequency (sdF0), while reduced intensity of speech variability or monoloudness will be assessed using the standard deviation of speech intensity (sdInt). To assess timing abnormalities seen in PD, prolonged pauses (PrLP), disrupting natural rhythm of speech, will be used. |
| Titel PART 2: Assessment of acoustic and linguistic speech features as proxy for behavior and cognitive changes in PD | 12 months | primary aim: To assess how paralinguistic speech content changes after STN-DBS intervention. Outcome: A compound score resulting from the normalized average of the main emotional paralinguistic features (such as pitch variability; duration of voiced segments, pause durations and intensity variability). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PART I/B: Safety measures for surgical interventions in PD | 12 months | secondary aim B: Comparison of paralinguistic speech outcomes before and 1-year after STN-DBS + BMT vs BMT alone. Outcome: Comparison of the rate of change of the compound score resulting from the normalized average of the main semantic features (such as content density, N-grams parameter, or moving-average type-token ratio). |
| PART II/C: Emotional and cognitive speech outcomes to be used in surgical and pharmacological interventions in PD | 12 months | secondary aim C: Assessment of capsular speech features outcome after STN-DBS in PD. Outcome: A compound score resulting from the normalized average of the main speech features affected by capsular stimulation induced side-effects (such as net speech rate and pitch breaks during sustained phonation). |
| PART I/A: Safety measures for surgical interventions in PD | 12 months | secondary aim A: Assessment of dyskinetic (hyperkinetic) motor speech features outcome after STN-DBS. Outcome: A compound score resulting from the normalized average of the main speech features affected by dyskinesia (such as intensity variability, breading capacity and spectral features variability). |
Countries
Germany, Netherlands, Switzerland
Contacts
Primary ContactSteffen Paschen, MD
Backup ContactGünter Deuschl, Prof. Dr.
Outcome results
None listed